GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Other Current Payables

Rize Oncology (XCNQ:RIZE) Other Current Payables : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Other Current Payables?

Rize Oncology's Other Current Payables for the quarter that ended in Dec. 2024 was C$0.00 Mil.


Rize Oncology Other Current Payables Historical Data

The historical data trend for Rize Oncology's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Other Current Payables Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
- - - - -

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rize Oncology Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Rize Oncology Other Current Payables Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Rize Oncology Business Description

Traded in Other Exchanges
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director

Rize Oncology Headlines

No Headlines